Navigation Links
Trials begin on potent new hepatitis C drug

The first clinical trials have started on a new investigational drug, discovered by researchers at Cardiff University, which is being developed to treat infections caused by Hepatitis C virus.

Approximately 170 million people worldwide are affected with Hepatitis C, which can lead to liver cancer, cirrhosis and death. It is the leading cause of liver transplantation in western countries. The current treatment involves two drugs ribavirin and interferon, which has to be given as an injection. Side effects are often severe and lead to patients failing to complete the treatment.

The new drug, INX-189, is taken orally and was first prepared at the Welsh School of Pharmacy in November 2008. Laboratory tests showed it killed 90 per cent of the virus at very low (nanomolar) concentration, making it one of the most potent compounds of its kind developed to date.

US pharmaceutical company Inhibitex, which owns the licence to INX-189 and has been working with the Cardiff team, has now started trials in healthy volunteers to assess the compound's safety. A second trial, which would evaluate the compound's effectiveness on Hepatitis patients, may follow later this year.

Professor Chris McGuigan of the Welsh School of Pharmacy, academic lead on the project, said: "This is still a very early stage of the trials process. However, progress has been encouraging so far, going from the laboratory to human trials within 18 months. We believe that INX-189 offers the possibility of more potency against Hepatitis, more rapid action in the liver, and fewer side effects than existing treatments."


Contact: Professor Chris McGuigan
Cardiff University

Page: 1

Related medicine news :

1. Quincy Bioscience Launches; Research Studies More Accessible For Participants
2. Accumed Research Associates Expands Capabilities In Phase I and Bioequivalence Clinical Trials
3. Scott & White Healthcare clinical trials target lymphoma, leukemia
4. Almac's North Carolina Facility Continues Growth in Academically Based Clinical Trials
5. MedTrials Launches New Online Training Website:
6. Experts Urge Fixes for Clinical Trials System in Crisis
7. SWOG cancer trials network awarded over $120 million in NCI grants
8. Almac to Improve Label Approval Process in Clinical Trials
9. Childhood cancer patients enrolled in clinical trials need clearer communication about their role
10. Medical schools partner to tackle barriers to minority participation in cancer clinical trials
11. Abbreviated Trials Yield Misleading Results: Study
Post Your Comments:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements owned by ... to enhance the health of felines. The formula is all-natural and is made from ... the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many women are ... with endometriosis. These women need a treatment plan to not only alleviate symptoms ... can help for preservation of fertility and ultimately achieving a pregnancy. The specialists ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
(Date:6/23/2016)... , June 23, 2016 Bracket , ... launch its next generation clinical outcomes platform, Bracket eCOA (SM) ... held on June 26 – 30, 2016 in ... first electronic Clinical Outcome Assessment product of its kind to ... #715. Bracket eCOA 6.0 is a flexible platform ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
Breaking Medicine Technology: